The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery

Pierre Bigot, Jean Christophe Bernhard, Inderbir S. Gill, Nam Son Vuong, Grégory Verhoest, Vincent Flamand, Boris Reix, Evren Suer, Ilker Gökce, Jean Baptiste Beauval, François Xavier Nouhaud, Masatoshi Eto, Eduard Baco, Toru Matsugasumi, Yvonne Chowaniec, Jérôme Rigaud, Claire Lenormand, Christian Pfister, Jean François Hetet, Guillaume PloussardMorgan Roupret, Priscilla Léon, Adnan El Bakri, Stéphane Larré, Xavier Tillou, Arnaud Doerfler, Aurélien Descazeaud, Nicolas Koutlidis, Alexandre Schneider, Philippe Sebe, Alexandre Ingels, Abdel Rahmène Azzouzi, Michel Soulié, Arnaud Méjean, Karim Bensalah, Jean Jacques Patard, members of the Kidney Cancer group of the CCAFU the members of the Kidney Cancer group of the CCAFU

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: To evaluate the oncological outcomes of papillary renal cell carcinoma (pRCC) following nephron sparing surgery (NSS) and to determine whether the subclassification type of pRCC could be a prognostic factor for recurrence, progression, and specific death. Materials and methods: An international multicentre retrospective study involving 19 institutions and the French network for research on kidney cancer was conducted after IRB approval. We analyzed data of all patients with pRCC who were treated by NSS between 2004 and 2014. Results: We included 486 patients. Tumors were type 1 pRCC in 369 (76 %) cases and type 2 pRCC in 117 (24 %) cases. After a mean follow-up of 35 (1–120) months, 8 (1.6 %) patients experienced a local recurrence, 12 (1.5 %) had a metastatic progression, 24 (4.9 %) died, and 7 (1.4 %) died from cancer. Patients with type I pRCC had more grade II (66.3 vs. 46.1 %; p < 0.001) and less grade III (20 vs. 41 %; p < 0.001) tumors. Three-year estimated cancer-free survival (CFS) rate for type 1 pRCC was 96.5 % and for type 2 pRCC was 95.1 % (p = 0.894), respectively. Three-year estimated cancer-specific survival rate for type 1 pRCC was 98.4 % and for type 2 pRCC was 97.3 % (p = 0.947), respectively. Tumor stage superior to pT1 was the only prognostic factor for CFS (HR 3.5; p = 0.03). Conclusion: Histological subtyping of pRCC has no impact on oncologic outcomes after nephron sparing surgery. In this selected population of pRCC tumors, we found that tumor stage is the only prognostic factor for cancer-free survival.

Original languageEnglish
Pages (from-to)347-352
Number of pages6
JournalWorld Journal of Urology
Volume34
Issue number3
DOIs
Publication statusPublished - Mar 1 2016
Externally publishedYes

Fingerprint

Nephrons
Renal Cell Carcinoma
Neoplasms
Survival Rate
Recurrence
Survival
Kidney Neoplasms
Research Ethics Committees
Multicenter Studies
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Bigot, P., Bernhard, J. C., Gill, I. S., Vuong, N. S., Verhoest, G., Flamand, V., ... the members of the Kidney Cancer group of the CCAFU, M. O. T. K. C. G. O. T. CCAFU. (2016). The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. World Journal of Urology, 34(3), 347-352. https://doi.org/10.1007/s00345-015-1634-0

The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. / Bigot, Pierre; Bernhard, Jean Christophe; Gill, Inderbir S.; Vuong, Nam Son; Verhoest, Grégory; Flamand, Vincent; Reix, Boris; Suer, Evren; Gökce, Ilker; Beauval, Jean Baptiste; Nouhaud, François Xavier; Eto, Masatoshi; Baco, Eduard; Matsugasumi, Toru; Chowaniec, Yvonne; Rigaud, Jérôme; Lenormand, Claire; Pfister, Christian; Hetet, Jean François; Ploussard, Guillaume; Roupret, Morgan; Léon, Priscilla; Bakri, Adnan El; Larré, Stéphane; Tillou, Xavier; Doerfler, Arnaud; Descazeaud, Aurélien; Koutlidis, Nicolas; Schneider, Alexandre; Sebe, Philippe; Ingels, Alexandre; Azzouzi, Abdel Rahmène; Soulié, Michel; Méjean, Arnaud; Bensalah, Karim; Patard, Jean Jacques; the members of the Kidney Cancer group of the CCAFU, members of the Kidney Cancer group of the CCAFU.

In: World Journal of Urology, Vol. 34, No. 3, 01.03.2016, p. 347-352.

Research output: Contribution to journalArticle

Bigot, P, Bernhard, JC, Gill, IS, Vuong, NS, Verhoest, G, Flamand, V, Reix, B, Suer, E, Gökce, I, Beauval, JB, Nouhaud, FX, Eto, M, Baco, E, Matsugasumi, T, Chowaniec, Y, Rigaud, J, Lenormand, C, Pfister, C, Hetet, JF, Ploussard, G, Roupret, M, Léon, P, Bakri, AE, Larré, S, Tillou, X, Doerfler, A, Descazeaud, A, Koutlidis, N, Schneider, A, Sebe, P, Ingels, A, Azzouzi, AR, Soulié, M, Méjean, A, Bensalah, K, Patard, JJ & the members of the Kidney Cancer group of the CCAFU, MOTKCGOTCCAFU 2016, 'The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery', World Journal of Urology, vol. 34, no. 3, pp. 347-352. https://doi.org/10.1007/s00345-015-1634-0
Bigot, Pierre ; Bernhard, Jean Christophe ; Gill, Inderbir S. ; Vuong, Nam Son ; Verhoest, Grégory ; Flamand, Vincent ; Reix, Boris ; Suer, Evren ; Gökce, Ilker ; Beauval, Jean Baptiste ; Nouhaud, François Xavier ; Eto, Masatoshi ; Baco, Eduard ; Matsugasumi, Toru ; Chowaniec, Yvonne ; Rigaud, Jérôme ; Lenormand, Claire ; Pfister, Christian ; Hetet, Jean François ; Ploussard, Guillaume ; Roupret, Morgan ; Léon, Priscilla ; Bakri, Adnan El ; Larré, Stéphane ; Tillou, Xavier ; Doerfler, Arnaud ; Descazeaud, Aurélien ; Koutlidis, Nicolas ; Schneider, Alexandre ; Sebe, Philippe ; Ingels, Alexandre ; Azzouzi, Abdel Rahmène ; Soulié, Michel ; Méjean, Arnaud ; Bensalah, Karim ; Patard, Jean Jacques ; the members of the Kidney Cancer group of the CCAFU, members of the Kidney Cancer group of the CCAFU. / The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. In: World Journal of Urology. 2016 ; Vol. 34, No. 3. pp. 347-352.
@article{4192986c4a51439383afa24d54bd3742,
title = "The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery",
abstract = "Objectives: To evaluate the oncological outcomes of papillary renal cell carcinoma (pRCC) following nephron sparing surgery (NSS) and to determine whether the subclassification type of pRCC could be a prognostic factor for recurrence, progression, and specific death. Materials and methods: An international multicentre retrospective study involving 19 institutions and the French network for research on kidney cancer was conducted after IRB approval. We analyzed data of all patients with pRCC who were treated by NSS between 2004 and 2014. Results: We included 486 patients. Tumors were type 1 pRCC in 369 (76 {\%}) cases and type 2 pRCC in 117 (24 {\%}) cases. After a mean follow-up of 35 (1–120) months, 8 (1.6 {\%}) patients experienced a local recurrence, 12 (1.5 {\%}) had a metastatic progression, 24 (4.9 {\%}) died, and 7 (1.4 {\%}) died from cancer. Patients with type I pRCC had more grade II (66.3 vs. 46.1 {\%}; p < 0.001) and less grade III (20 vs. 41 {\%}; p < 0.001) tumors. Three-year estimated cancer-free survival (CFS) rate for type 1 pRCC was 96.5 {\%} and for type 2 pRCC was 95.1 {\%} (p = 0.894), respectively. Three-year estimated cancer-specific survival rate for type 1 pRCC was 98.4 {\%} and for type 2 pRCC was 97.3 {\%} (p = 0.947), respectively. Tumor stage superior to pT1 was the only prognostic factor for CFS (HR 3.5; p = 0.03). Conclusion: Histological subtyping of pRCC has no impact on oncologic outcomes after nephron sparing surgery. In this selected population of pRCC tumors, we found that tumor stage is the only prognostic factor for cancer-free survival.",
author = "Pierre Bigot and Bernhard, {Jean Christophe} and Gill, {Inderbir S.} and Vuong, {Nam Son} and Gr{\'e}gory Verhoest and Vincent Flamand and Boris Reix and Evren Suer and Ilker G{\"o}kce and Beauval, {Jean Baptiste} and Nouhaud, {Fran{\cc}ois Xavier} and Masatoshi Eto and Eduard Baco and Toru Matsugasumi and Yvonne Chowaniec and J{\'e}r{\^o}me Rigaud and Claire Lenormand and Christian Pfister and Hetet, {Jean Fran{\cc}ois} and Guillaume Ploussard and Morgan Roupret and Priscilla L{\'e}on and Bakri, {Adnan El} and St{\'e}phane Larr{\'e} and Xavier Tillou and Arnaud Doerfler and Aur{\'e}lien Descazeaud and Nicolas Koutlidis and Alexandre Schneider and Philippe Sebe and Alexandre Ingels and Azzouzi, {Abdel Rahm{\`e}ne} and Michel Souli{\'e} and Arnaud M{\'e}jean and Karim Bensalah and Patard, {Jean Jacques} and {the members of the Kidney Cancer group of the CCAFU}, {members of the Kidney Cancer group of the CCAFU}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00345-015-1634-0",
language = "English",
volume = "34",
pages = "347--352",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery

AU - Bigot, Pierre

AU - Bernhard, Jean Christophe

AU - Gill, Inderbir S.

AU - Vuong, Nam Son

AU - Verhoest, Grégory

AU - Flamand, Vincent

AU - Reix, Boris

AU - Suer, Evren

AU - Gökce, Ilker

AU - Beauval, Jean Baptiste

AU - Nouhaud, François Xavier

AU - Eto, Masatoshi

AU - Baco, Eduard

AU - Matsugasumi, Toru

AU - Chowaniec, Yvonne

AU - Rigaud, Jérôme

AU - Lenormand, Claire

AU - Pfister, Christian

AU - Hetet, Jean François

AU - Ploussard, Guillaume

AU - Roupret, Morgan

AU - Léon, Priscilla

AU - Bakri, Adnan El

AU - Larré, Stéphane

AU - Tillou, Xavier

AU - Doerfler, Arnaud

AU - Descazeaud, Aurélien

AU - Koutlidis, Nicolas

AU - Schneider, Alexandre

AU - Sebe, Philippe

AU - Ingels, Alexandre

AU - Azzouzi, Abdel Rahmène

AU - Soulié, Michel

AU - Méjean, Arnaud

AU - Bensalah, Karim

AU - Patard, Jean Jacques

AU - the members of the Kidney Cancer group of the CCAFU, members of the Kidney Cancer group of the CCAFU

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objectives: To evaluate the oncological outcomes of papillary renal cell carcinoma (pRCC) following nephron sparing surgery (NSS) and to determine whether the subclassification type of pRCC could be a prognostic factor for recurrence, progression, and specific death. Materials and methods: An international multicentre retrospective study involving 19 institutions and the French network for research on kidney cancer was conducted after IRB approval. We analyzed data of all patients with pRCC who were treated by NSS between 2004 and 2014. Results: We included 486 patients. Tumors were type 1 pRCC in 369 (76 %) cases and type 2 pRCC in 117 (24 %) cases. After a mean follow-up of 35 (1–120) months, 8 (1.6 %) patients experienced a local recurrence, 12 (1.5 %) had a metastatic progression, 24 (4.9 %) died, and 7 (1.4 %) died from cancer. Patients with type I pRCC had more grade II (66.3 vs. 46.1 %; p < 0.001) and less grade III (20 vs. 41 %; p < 0.001) tumors. Three-year estimated cancer-free survival (CFS) rate for type 1 pRCC was 96.5 % and for type 2 pRCC was 95.1 % (p = 0.894), respectively. Three-year estimated cancer-specific survival rate for type 1 pRCC was 98.4 % and for type 2 pRCC was 97.3 % (p = 0.947), respectively. Tumor stage superior to pT1 was the only prognostic factor for CFS (HR 3.5; p = 0.03). Conclusion: Histological subtyping of pRCC has no impact on oncologic outcomes after nephron sparing surgery. In this selected population of pRCC tumors, we found that tumor stage is the only prognostic factor for cancer-free survival.

AB - Objectives: To evaluate the oncological outcomes of papillary renal cell carcinoma (pRCC) following nephron sparing surgery (NSS) and to determine whether the subclassification type of pRCC could be a prognostic factor for recurrence, progression, and specific death. Materials and methods: An international multicentre retrospective study involving 19 institutions and the French network for research on kidney cancer was conducted after IRB approval. We analyzed data of all patients with pRCC who were treated by NSS between 2004 and 2014. Results: We included 486 patients. Tumors were type 1 pRCC in 369 (76 %) cases and type 2 pRCC in 117 (24 %) cases. After a mean follow-up of 35 (1–120) months, 8 (1.6 %) patients experienced a local recurrence, 12 (1.5 %) had a metastatic progression, 24 (4.9 %) died, and 7 (1.4 %) died from cancer. Patients with type I pRCC had more grade II (66.3 vs. 46.1 %; p < 0.001) and less grade III (20 vs. 41 %; p < 0.001) tumors. Three-year estimated cancer-free survival (CFS) rate for type 1 pRCC was 96.5 % and for type 2 pRCC was 95.1 % (p = 0.894), respectively. Three-year estimated cancer-specific survival rate for type 1 pRCC was 98.4 % and for type 2 pRCC was 97.3 % (p = 0.947), respectively. Tumor stage superior to pT1 was the only prognostic factor for CFS (HR 3.5; p = 0.03). Conclusion: Histological subtyping of pRCC has no impact on oncologic outcomes after nephron sparing surgery. In this selected population of pRCC tumors, we found that tumor stage is the only prognostic factor for cancer-free survival.

UR - http://www.scopus.com/inward/record.url?scp=84959324456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959324456&partnerID=8YFLogxK

U2 - 10.1007/s00345-015-1634-0

DO - 10.1007/s00345-015-1634-0

M3 - Article

C2 - 26149352

AN - SCOPUS:84959324456

VL - 34

SP - 347

EP - 352

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -